Who
Robert L. Rosiello
Director
Company insider
Files Form 4 as: Director, Seres Therapeutics; Director, Sana Biotechnology; Director, Omega Therapeutics; Director, Evelo Biosciences; Director, Axcella Health; EVP, Corp Dev & Strategy, Bausch Health Companies.
In numbers
- Trades disclosed
- 23
- Buys
- 3
- Sells
- 0
- Bought
- $5.0M
- Sold
- $0
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 12 Jun 2015
- Last trade
- 8 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,500 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,508 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,508 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 4 Jun 2026filed 5 Jun 2026 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 5 Aug 2025filed 6 Aug 2025 | MCRB Seres Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 2 Oct 2024filed 4 Oct 2024 | Omega Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 8 Jun 2023filed 12 Jun 2023 | Evelo Biosciencesoption or derivative | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 14 Apr 2023filed 18 Apr 2023 | Evelo Biosciencesoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 16 Nov 2022filed 18 Nov 2022 | Axcella Healthoption or derivative | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 5 Dec 2016filed 7 Dec 2016 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code F | $264K14,687 at $18.00 | filing |
| 4 Nov 2016filed 8 Nov 2016 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code F | $18K817 at $22.06 | filing |
| 3 Aug 2016filed 5 Aug 2016 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code F | $31K1,338 at $23.54 | filing |
| 12 May 2016filed 16 May 2016 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —84,975 at $0.00 | filing |
| 20 Oct 2015filed 22 Oct 2015 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —7,875 at $0.00 | filing |
| 31 Jul 2015filed 3 Aug 2015 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Bought | $181K704 at $257.25 | filing |
| 30 Jul 2015filed 3 Aug 2015 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Bought | $1.8M7,171 at $253.99 | filing |
| 20 Jul 2015filed 22 Jul 2015 | BHC Bausch Health CompaniesPharmaceuticals | SEC FORM 4 Code A | —12,900 at $0.00 | filing |
News
Contrasting Ocular Therapeutix (NASDAQ:OCUL) and Bausch Health Cos (NYSE:BHC)BHC · dailypolitical.com · 13 Oct 2026Contrasting Bausch Health Cos (NYSE:BHC) and Journey Medical (NASDAQ:DERM)BHC · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name Robert L. Rosiello; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.